IP Library Granted Patent US 11,873,504
Granted Patent B2
US 11,873,504 · App. 16/335,516 · Granted Jan 16, 2024

RNA-guided nucleic acid modifying enzymes and methods of use thereof

Inventors: Jennifer A Doudna (Berkeley, CA); Jillian F. Banfield (Berkeley, CA); David Burstein (Berkeley, CA); Lucas Benjamin Harrington (Berkeley, CA); Steven C. Strutt (Berkeley, CA)
Assignee: The Regents of the University of California
C12N15/8509C07K19/00C12N9/1007C12N9/1025C12N9/22C12N15/102C12N15/113C12N15/52C12N15/62C12N15/74C12N15/85C12N15/86C12N15/88C12N15/902C07K2319/02C07K2319/03C07K2319/06C07K2319/09C07K2319/20C12N2310/20C12N2740/13043C12N2740/16043C12N2750/14143
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,873,504
App. No.
16/335,516
Granted
Jan 16, 2024
Kind
B2
Abstract

The present disclosure provides CasX proteins, nucleic acids encoding the CasX proteins, and modified host cells comprising the CasX proteins and/or nucleic acids encoding same. CasX proteins are useful in a variety of applications, which are provided. The present disclosure provides CasX guide RNAs that bind to and provide sequence specificity to the CasX proteins, nucleic acids encoding the CasX guide RNAs, and modified host cells comprising the CasX guide RNAs and/or nucleic acids encoding same. CasX guide RNAs are useful in a variety of applications, which are provided. The present disclosure provides archaeal Cas9 polypeptides and nucleic acids encoding same, as well as their associated archaeal Cas9 guide RNAs and nucleic acids encoding same.

Claims (41)

1. One or more nucleic acid molecules encoding one or more of:

(a) a CasX guide RNA comprising an activator RNA and a targeter RNA, wherein the targeter RNA is heterologous to the activator RNA,

wherein one nucleic molecule comprises a first nucleotide sequence encoding the activator RNA and a second nucleotide sequence encoding the targeter RNA, wherein the first nucleotide sequence is heterologous to the second nucleotide sequence, or

wherein a first nucleic molecule comprises a nucleotide sequence encoding the activator RNA and a second nucleic molecule comprises a nucleotide sequence encoding the targeter RNA, wherein the first nucleic molecule is heterologous to the second nucleic molecule,

and

wherein the targeter RNA comprises (i) a guide sequence that hybridizes to a target nucleic acid, and (ii) a duplex-forming segment and the activator RNA hybridizes with the duplex-forming segment to form a double stranded RNA (dsRNA) duplex that binds a CasX polypeptide and guides the bound CasX polypeptide to the target nucleic acid;

(b) a CasX polypeptide, wherein the one nucleic acid molecule comprises a promoter operably linked to and heterologous to the sequence encoding the CasX polypeptide; and

(c) a CasX fusion polypeptide comprising a CasX polypeptide fused to a heterologous polypeptide, wherein the one nucleic acid molecule comprises a nucleotide sequence encoding the CasX fusion polypeptide.

2. The one or more nucleic acid molecules of claim 1 , wherein the CasX polypeptide comprises an amino acid sequence having 85% or more, 90% or more, 95% or more, 97% or more, 98% or more, 99% or more, or 100% sequence identity to the amino acid sequence set forth in SEQ ID NO:1 or SEQ ID NO:2.

3. The one or more nucleic acid molecules of claim 1 , wherein the CasX guide RNA is a single guide RNA.

4. The one or more nucleic acid molecules of claim 1 , wherein the CasX guide RNA is a dual-guide RNA.

5. The one or more nucleic acid molecules of claim 1 , wherein the promoter is functional in a eukaryotic cell.

6. The one or more nucleic acid molecules of claim 1 , wherein the one or more nucleic acid molecules is one or more recombinant expression vectors.

7. The one or more nucleic acid molecules of claim 6 , wherein the one or more recombinant expression vectors are selected from: one or more adeno-associated viral vectors, one or more recombinant retroviral vectors, and one or more recombinant lentiviral vectors.

8. An isolated eukaryotic cell comprising one or more of:

a) a CasX polypeptide, or a nucleic acid molecule encoding the CasX polypeptide,

b) a CasX fusion polypeptide, or a nucleic acid molecule encoding the CasX fusion polypeptide, wherein the CasX fusion polypeptide comprises a CasX polypeptide fused to a heterologous polypeptide, and

c) a CasX guide RNA, or a nucleic acid molecule encoding the CasX guide RNA, wherein the CasX guide RNA comprises (i) a targeter sequence comprising a guide sequence that hybridizes to a target nucleic acid, and a duplex-forming segment; and (ii) an activator sequence that hybridizes with the duplex-forming segment of the targeter sequence to form a double stranded RNA(dsRNA) duplex that binds the CasX polypeptide and guides the bound CasX polypeptide to the target nucleic acid.

9. The isolated eukaryotic cell of claim 8 , comprising the nucleic acid molecule encoding the CasX polypeptide, wherein said nucleic acid molecule is integrated into the genomic DNA of the cell.

10. The isolated eukaryotic cell of claim 8 , wherein the eukaryotic cell is a plant cell, a mammalian cell, an insect cell, an arachnid cell, a fungal cell, a bird cell, a reptile cell, an amphibian cell, an invertebrate cell, a mouse cell, a rat cell, a primate cell, a non-human primate cell, or a human cell.

11. An isolated cell comprising a CasX fusion polypeptide comprising a CasX polypeptide fused to a heterologous polypeptide, or a nucleic acid molecule encoding the CasX fusion polypeptide, wherein the isolated cell is a prokaryotic cell.

12. The isolated cell of claim 11 , comprising the nucleic acid molecule encoding the CasX fusion polypeptide, wherein said nucleic acid molecule is integrated into the genomic DNA of the cell.

13. The one or more nucleic acid molecules of claim 1 , wherein the heterologous polypeptide is fused to the N- or the C-terminus of the CasX polypeptide.

14. The one or more nucleic acid molecules of claim 1 , wherein the heterologous polypeptide exhibits an enzymatic activity that modifies target DNA.

15. The one or more nucleic acid molecules of claim 1 , wherein the heterologous polypeptide exhibits an enzymatic activity that modifies a target polypeptide associated with a target nucleic acid.

16. The one or more nucleic acid molecules of claim 1 , wherein the heterologous polypeptide is an endosomal escape polypeptide.

17. The one or more nucleic acid molecules of claim 1 , wherein the heterologous polypeptide is a chloroplast transit peptide.

18. The one or more nucleic acid molecules of claim 1 , wherein the CasX guide RNA comprises a nucleotide sequence having 80% or more, 85% or more, 90% or more, 93% or more, 95% or more, 97% or more, 98% or more, or 100% identity to the nucleotide sequence set forth in any one of SEQ ID NOs:11-17, 21-28, 31-34, 41-43, and 61.

19. The eukaryotic cell of claim 8 , wherein the CasX polypeptide comprises an amino acid sequence having 85% or more, 90% or more, 95% or more, 97% or more, 98% or more, 99% or more, or 100% sequence identity to the amino acid sequence set forth in SEQ ID NO:1 or SEQ ID NO:2.

20. The eukaryotic cell of claim 8 , wherein the CasX polypeptide can catalyze a double strand break in a target double-stranded DNA.

21. The eukaryotic cell of claim 8 , wherein the CasX polypeptide is a nickase that can cleave only one strand of a double-stranded target nucleic acid molecule.

22. The eukaryotic cell of claim 8 , wherein the CasX polypeptide is a catalytically inactive CasX polypeptide (dCasX).

23. The eukaryotic cell of claim 8 , wherein the CasX polypeptide comprises one or more mutations at a position corresponding to those selected from: D672, E769, and D935 of SEQ ID NO: 1.

24. The eukaryotic cell of claim 8 , wherein the heterologous polypeptide is fused to the N- or the C-terminus of the CasX polypeptide.

25. The eukaryotic cell of claim 8 , wherein the heterologous polypeptide exhibits an enzymatic activity that modifies target DNA.

26. The eukaryotic cell of claim 8 , wherein the heterologous polypeptide exhibits an enzymatic activity that modifies a target polypeptide associated with a target nucleic acid.

27. The eukaryotic cell of claim 8 , wherein the heterologous polypeptide is an endosomal escape polypeptide.

28. The eukaryotic cell of claim 8 , wherein the heterologous polypeptide is a chloroplast transit peptide.

29. The eukaryotic cell of claim 8 , wherein the guide RNA comprises a nucleotide sequence having 80% or more, 85% or more, 90% or more, 93% or more, 95% or more, 97% or more, 98% or more, or 100% identity to the nucleotide sequence set forth in any one of SEQ ID NOs: 11-17, 21-28, 31-34, 41-43, and 61.

30. The one or more nucleic acid molecules of claim 1 , wherein the one or more nucleic acid molecules encode a detectable label.

31. The one or more nucleic acid molecules of claim 30 , wherein the detectable label comprises a fluorophore.

Assignments (7)
CORRECTION BY DECLARATION TO CORRECT CONVEYANCE AND DOCUMENTS ERRONEOUSLY FILED AT 057525/0141 Recorded Sep 19, 2023
From: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
To: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
Reel/Frame 064953/0509 →
CORRECTION BY DECLARATION TO CORRECT CONVEYANCE AND DOCUMENTS ERRONEOUSLY FILED AT 055223/0805 Recorded Sep 19, 2023
From: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
To: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
Reel/Frame 064953/0485 →
CONFIRMATORY LICENSE Recorded May 10, 2023
From: UNIVERSITY OF CALIFORNIA BERKELEY
To: NATIONAL SCIENCE FOUNDATION
Reel/Frame 063592/0592 →
CORRECTIVE BY NULLIFICATION TO CORRECT INCORRECTLY RECORDED APPLICATION/PATENT NUMBERS (SEE ATTACHMENT) AT REEL/FRAME 055223/0805. ASSIGNOR HEREBY CONFIRMS THE CHANGE OF ADDRESS. Recorded Sep 16, 2021
From: MAMMOTH BIOSCIENCES, INC.
To: MAMMOTH BIOSCIENCES, INC.
Reel/Frame 057525/0141 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 15, 2021
From: DOUDNA, JENNIFER A.; BANFIELD, JILLIAN F.; BURSTEIN, DAVID; HARRINGTON, LUCAS BENJAMIN; STRUTT, STEVEN C.
To: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
Reel/Frame 055936/0361 →
CHANGE OF ADDRESS OF THE ASSIGNEE Recorded Feb 4, 2021
From: MAMMOTH BIOSCIENCES, INC.
To: MAMMOTH BIOSCIENCES, INC.
Reel/Frame 055223/0805 →
CONFIRMATORY LICENSE Recorded Nov 13, 2020
From: UNIVERSITY OF CALIFORNIA, BERKELEY
To: NATIONAL SCIENCE FOUNDATION
Reel/Frame 054414/0506 →
Continuity (2)
Provisional Application 62402846 · Sep 30, 2016
Related Publication 20200017879A1 · Jan 16, 2020
Cited By (8)
US 12,227,753 US 12,551,560 US 12,551,573 US 12,553,037 US 12,559,743 US 12,594,349 US 12,637,691 US 12,674,149